CA1338982C - Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes - Google Patents

Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes

Info

Publication number: CA1338982C
Authority: CA; Canada
Prior art keywords: antibody; leukocyte; conjugate; antibodies; lesion
Prior art date: 1989-07-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 615460

Other languages

English (en)

Inventor

Hans John Hansen

Milton David Goldenberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunomedics Inc

Original Assignee

Immunomedics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-27

Filing date

1989-09-29

Publication date

1997-03-11

1989-09-29 Application filed by Immunomedics Inc filed Critical Immunomedics Inc

1997-03-11 Application granted granted Critical

1997-03-11 Publication of CA1338982C publication Critical patent/CA1338982C/fr

2014-03-11 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000003902 lesion Effects 0.000 title claims abstract description 56
208000015181 infectious disease Diseases 0.000 title claims abstract description 35
230000002458 infectious effect Effects 0.000 title claims abstract description 28
230000002757 inflammatory effect Effects 0.000 title claims abstract description 21
229940127121 immunoconjugate Drugs 0.000 title claims abstract description 13
238000001514 detection method Methods 0.000 title claims description 15
239000002131 composite material Substances 0.000 claims abstract description 81
210000000265 leukocyte Anatomy 0.000 claims abstract description 72
238000000034 method Methods 0.000 claims abstract description 62
239000003795 chemical substances by application Substances 0.000 claims abstract description 36
230000008685 targeting Effects 0.000 claims abstract description 36
238000003384 imaging method Methods 0.000 claims abstract description 26
102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 25
108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 25
239000012216 imaging agent Substances 0.000 claims abstract description 19
241000124008 Mammalia Species 0.000 claims abstract description 8
239000012634 fragment Substances 0.000 claims description 63
239000000427 antigen Substances 0.000 claims description 40
108091007433 antigens Proteins 0.000 claims description 40
102000036639 antigens Human genes 0.000 claims description 40
238000002360 preparation method Methods 0.000 claims description 25
210000003714 granulocyte Anatomy 0.000 claims description 18
210000001744 T-lymphocyte Anatomy 0.000 claims description 17
210000003719 b-lymphocyte Anatomy 0.000 claims description 16
210000001616 monocyte Anatomy 0.000 claims description 16
230000004807 localization Effects 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 9
239000007924 injection Substances 0.000 claims description 9
230000005291 magnetic effect Effects 0.000 claims description 8
230000002708 enhancing effect Effects 0.000 claims description 7
ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims description 5
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
230000005855 radiation Effects 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 abstract description 30
239000004599 antimicrobial Substances 0.000 abstract description 9
239000000562 conjugate Substances 0.000 description 41
239000003814 drug Substances 0.000 description 39
229940079593 drug Drugs 0.000 description 26
238000002595 magnetic resonance imaging Methods 0.000 description 15
239000002738 chelating agent Substances 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 13
229940124597 therapeutic agent Drugs 0.000 description 12
238000011282 treatment Methods 0.000 description 12
239000003981 vehicle Substances 0.000 description 12
229920002307 Dextran Polymers 0.000 description 11
230000003115 biocidal effect Effects 0.000 description 11
125000005647 linker group Chemical group 0.000 description 11
239000000203 mixture Substances 0.000 description 11
241000894007 species Species 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
230000005298 paramagnetic effect Effects 0.000 description 10
108060003951 Immunoglobulin Proteins 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
230000000694 effects Effects 0.000 description 8
102000018358 immunoglobulin Human genes 0.000 description 8
150000002500 ions Chemical class 0.000 description 8
238000002372 labelling Methods 0.000 description 8
-1 or other enzymatic Substances 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
125000003172 aldehyde group Chemical group 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
206010037660 Pyrexia Diseases 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000007796 conventional method Methods 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
238000007911 parenteral administration Methods 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
230000009467 reduction Effects 0.000 description 6
230000007017 scission Effects 0.000 description 6
125000003396 thiol group Chemical group [H]S* 0.000 description 6
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000000032 diagnostic agent Substances 0.000 description 5
229940039227 diagnostic agent Drugs 0.000 description 5
238000002059 diagnostic imaging Methods 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 4
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
102000057297 Pepsin A Human genes 0.000 description 4
108090000284 Pepsin A Proteins 0.000 description 4
239000002262 Schiff base Substances 0.000 description 4
150000004753 Schiff bases Chemical class 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
229910052796 boron Inorganic materials 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
125000000524 functional group Chemical group 0.000 description 4
229940111202 pepsin Drugs 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
150000003573 thiols Chemical class 0.000 description 4
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
206010000269 abscess Diseases 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
150000001718 carbodiimides Chemical class 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
150000004985 diamines Chemical class 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
229940102223 injectable solution Drugs 0.000 description 3
238000011068 loading method Methods 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
230000008807 pathological lesion Effects 0.000 description 3
229920000768 polyamine Polymers 0.000 description 3
238000000163 radioactive labelling Methods 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
239000008174 sterile solution Substances 0.000 description 3
231100001274 therapeutic index Toxicity 0.000 description 3
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 3
XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 2
VGHPYIHJEJAJJZ-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione;pyrrole-2,5-dione Chemical class O=C1NC(=O)C=C1.OC1CC(=O)NC1=O VGHPYIHJEJAJJZ-UHFFFAOYSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010031252 Osteomyelitis Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
150000002466 imines Chemical class 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
150000002540 isothiocyanates Chemical class 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000007170 pathology Effects 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Inorganic materials [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000006894 reductive elimination reaction Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002603 single-photon emission computed tomography Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
229960001082 trimethoprim Drugs 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
MPTQLFFTNNKMRP-UHFFFAOYSA-N 3,4-dihydroxypyrrolidine-2,5-dione Chemical class OC1C(O)C(=O)NC1=O MPTQLFFTNNKMRP-UHFFFAOYSA-N 0.000 description 1
JDXQWYKOKYUQDN-UHFFFAOYSA-N 3-hydroxypyrrolidine-2,5-dione Chemical class OC1CC(=O)NC1=O JDXQWYKOKYUQDN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical class [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108010027164 Amanitins Proteins 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
OSNZINYBJQTKQS-LAQSRHRBSA-L C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.[Zn+2] Chemical compound C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.[Zn+2] OSNZINYBJQTKQS-LAQSRHRBSA-L 0.000 description 1
102000004500 CCR1 Receptors Human genes 0.000 description 1
108010017319 CCR1 Receptors Proteins 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
108010023729 Complement 3d Receptors Proteins 0.000 description 1
102000011412 Complement 3d Receptors Human genes 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
208000037194 Fever of Unknown Origin Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical class C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
231100000111 LD50 Toxicity 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
241001632427 Radiola Species 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
RUDNHCHNENLLKM-UHFFFAOYSA-N ac1mj1v6 Chemical compound O=C1NC(CC(O)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CSC1=C2C2=CC=C(O)C=C2N1 RUDNHCHNENLLKM-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000611 antibody drug conjugate Substances 0.000 description 1
229940049595 antibody-drug conjugate Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
RYXHOMYVWAEKHL-OUBTZVSYSA-N astatine-211 Chemical compound [211At] RYXHOMYVWAEKHL-OUBTZVSYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000000981 bystander Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000013522 chelant Substances 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000958 deferoxamine Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002289 effect on microbe Effects 0.000 description 1
230000005264 electron capture Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
229960004413 flucytosine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000012817 gel-diffusion technique Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000000879 imine group Chemical group 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002075 inversion recovery Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
229940044173 iodine-125 Drugs 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229960003350 isoniazid Drugs 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000006263 metalation reaction Methods 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000032696 parturition Effects 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
229920003192 poly(bis maleimide) Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000002028 premature Effects 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
238000012545 processing Methods 0.000 description 1
AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical class NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
238000002601 radiography Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004513 sizing Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000005477 standard model Effects 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
229940041022 streptomycins Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA 615460 1989-07-27 1989-09-29 Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes Expired - Lifetime CA1338982C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38604789A	1989-07-27	1989-07-27
US386,047		1989-07-27

Publications (1)

Publication Number	Publication Date
CA1338982C true CA1338982C (fr)	1997-03-11

Family

ID=23523933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 615460 Expired - Lifetime CA1338982C (fr)	1989-07-27	1989-09-29	Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes

Country Status (1)

Country	Link
CA (1)	CA1338982C (fr)

1989
- 1989-09-29 CA CA 615460 patent/CA1338982C/fr not_active Expired - Lifetime

Legal Events

Date	Code	Title	Description
2014-05-13	MKEX	Expiry	Effective date: 20140311

Publication	Publication Date	Title
EP0353960B1 (fr)	1993-05-26	Conjugué antileukocyte polyspécifique pour la détection et le traitement de lésions infectieuses et inflammatoires
US5637288A (en)	1997-06-10	Chimeric antibody for detection and therapy of infectious and inflammatory lesions
AU657553B2 (en)	1995-03-16	Detection of cardiovascular lesions
US6548275B2 (en)	2003-04-15	Detection and treatment of infections with immunoconjugates
US5439665A (en)	1995-08-08	Detection and treatment of infectious and inflammatory lesions
CA1339415C (fr)	1997-09-02	Detection et traitement des infections au moyen d'immunoconjugues
CA1338982C (fr)	1997-03-11	Detection de lesions infectieuses et inflammatoires a l'aide de conjugues anticorps anti-leucocytes